August 2021: Pembrolizumab (Keytruda, Merck) iyadoo la raacayo lenvatinib (Lenvima, Eisai) waxaa ansixiyay Maamulka Cuntada iyo Dawooyinka bukaanada qaba kansarka endometrial sare oo aan ahayn xasilloonida microsatellite-sare (MSI-H) ama dayactir aan habboonayn (dMMR), kuwaas oo leh horumarka cudurka ka dib daweyntii hore ee nidaamka goob kasta oo aan ahayn musharraxiin qalliin daaweyn ah ama shucaac.
Sebtembar 17, 2019, FDA waxay siisay pembrolizumab oo ay weheliso lenvatinib oggolaanshaha degdega ah ee kansarka endometrial sare. Xarun-badan, calaamad-furan, aan kala sooc lahayn, daraasad firfircoon oo la xakameeyey 309/KEYNOTE-775 (NCT03517449) waxay ahayd lagama maarmaan si loo xaqiijiyo faa'iidada bukaan-socodka ee oggolaanshahan la dedejiyey.
827 bukaan oo qaba kansarka endometrial sare ayaa lagu qoray Daraasada 309/KEYNOTE-775, kuwaas oo hore u lahaa ugu yaraan hal daawaynta kiimiko ku salaysan platinum goob kasta, oo ay ku jiraan daawaynta neoadjuvant iyo adjuvant. Bukaan-socodka ayaa si aan kala sooc lahayn loogu qoondeeyay (1: 1) si ay u helaan pembrolizumab 200 mg xididka 3 toddobaad kasta oo leh lenvatinib 20 mg afka hal mar maalintii, ama doxorubicin ama paclitaxel, sida uu go'aamiyay baaruhu.
Badbaadada xorta ah ee horumarka (PFS), sida lagu go'aamiyay indhoolayaasha madaxa banaan ee dib u eegista dhexe (BICR), iyo guud ahaan badbaadada (OS) ayaa ahaa cabirada natiijada waxtarka aasaasiga ah. Heerka jawaabta ujeedka ah (ORR) iyo muddada jawaabta (DOR), labaduba ay qiimeeyeen BICR, waxay ahaayeen cabbirro natiijo waxtar oo dheeri ah.
Dhexdhexaadiyaha PFS ee bukaanada qaba kansarka endometrial ee horumarsan oo aan ahayn MSI-H ama dMMR wuxuu ahaa 6.6 bilood (95 boqolkiiba CI: 5.6, 7.4) kuwa qaata pembrolizumab iyo lenvatinib iyo 3.8 bilood (95 boqolkiiba CI: 3.6, 5.0) kuwa qaata baaritaanka kiimoterabi ee doorashada baaraha (HR 0.60; 95 boqolkiiba CI: 0.50, 0.72; p0.0001) ee kuwa qaata kiimoteraabiga doorashada baaraha. Dhexdhexaadiyaha OS wuxuu ahaa 17.4 bilood (95 boqolkiiba dhexgalka kalsoonida: 14.2, 19.9) ragga iyo 12.0 bilood (95 boqolkiiba dhexgalka kalsoonida: 10.8, 13.3) dumarka (HR 0.68; 95 boqolkiiba dhexgalka kalsoonida: 0.56, 0.84; p = 0.0001) . ORRs waxay ahaayeen 30% (95 boqolkiiba inta u dhaxaysa kalsoonida: 26, 36) iyo 15% (95 boqolkiiba dhexgalka kalsoonida: 12, 19), siday u kala horreeyaan (p0.0001). 9.2 bilood (1.6+, 23.7+) iyo 5.7 bilood (0.0+, 24.2+) waxay ahaayeen DOR -yada dhexdhexaadka ah.
Hypothyroidism, dhiig karka, daal, shuban, xanuunada muruqyada, lallabbo, rabitaanka cuntada oo hoos u dhacda, matag, stomatitis, miisaanka oo yaraada, calool xanuun, caabuq kaadi mareenka, proteinuria, calool istaag, madax xanuun, dhacdooyinka dhiigbaxa, palmar-plantar erythrodysestrophy, palmar-plantar erythrodysestrophy, palmar -plantar erythrodysestrophy, palmar-plantar erythro
Pembrolizumab 200 mg every 3 weeks or 400 mg every 6 weeks with lenvatinib 20 mg orally once daily is the recommended dose for endometrial cancer.
Tixraaca: https://www.fda.gov/
Fiiri faahfaahinta halkan.
